A Phase 2, Open-Label Study to Investigate the Efficacy and Safety of an 8-Week and 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 4 Hepatitis C Virus Infection With and Without Cirrhosis
Overview
- Phase
- Phase 2
- Intervention
- Simeprevir
- Conditions
- Chronic Hepatitis C
- Sponsor
- Peter J. Ruane, M.D.
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Sustained Virologic Response 12 Weeks after Treatment Completion (SVR12)
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
This study will look at the safety and efficacy of 8 week and 12 week treatment with Sofosbuvir and Simeprevir in treatment-naïve and treatment-experienced patients with chronic hepatitis C genotype 4.
Detailed Description
Patients with confirmed absence of cirrhosis will receive 8 weeks of treatment with Sofosbuvir and Simeprevir. Patients with confirmed presence of cirrhosis will receive 12 weeks of treatment with Sofosbuvir and Simeprevir. All patients will followed for 24 weeks post-treatment. Presence or absence of cirrhosis will be evaluated by FibroScan if no historical liver biopsy or FibroScan is available.
Investigators
Peter J. Ruane, M.D.
Principal Investigator, President
Peter J. Ruane, M.D., Inc.
Eligibility Criteria
Inclusion Criteria
- •HCV genotype 4 infection
- •HCV RNA \>10,000 IU/mL at screening.
Exclusion Criteria
- •Evidence of clinical hepatic decompensation (history or current evidence of ascites, bleeding varices or hepatic encephalopathy).
- •Any liver disease of non-HCV etiology. This includes, but is not limited to, acute hepatitis A, drug- or alcohol-related liver disease, autoimmune hepatitis, hemochromatosis, Wilson's disease, alpha-1 antitrypsin deficiency, non-alcoholic steatohepatitis, primary biliary cirrhosis, or any other non-HCV liver disease considered clinically significant by the investigator.
- •Infection/co-infection with HCV non-genotype
- •Co-infection with human immunodeficiency virus (HIV) type 1 or type 2 (HIV-1 or HIV-2) (positive HIV-1 or HIV-2 antibodies test at screening).
- •Co-infection with hepatitis-B virus (hepatitis-B-surface-antigen \[HBsAg\] positive).
- •Presence of significant co-morbidities or conditions that would compromise the subject's safety and could interfere with the subject's participation for the full duration of the study in the opinion of the investigator
- •Previously been treated with any direct acting anti-HCV agent (approved or investigational) for chronic HCV infection.
Arms & Interventions
Cirrhosis
Patients with confirmed presence of cirrhosis will received 12 weeks of treatment with Sofosbuvir and Simeprevir
Intervention: Simeprevir
Cirrhosis
Patients with confirmed presence of cirrhosis will received 12 weeks of treatment with Sofosbuvir and Simeprevir
Intervention: Sofosbuvir
Non-Cirrhotic
Patients with confirmed absence of cirrhosis will received 8 weeks of treatment with Sofosbuvir and Simeprevir
Intervention: Simeprevir
Non-Cirrhotic
Patients with confirmed absence of cirrhosis will received 8 weeks of treatment with Sofosbuvir and Simeprevir
Intervention: Sofosbuvir
Outcomes
Primary Outcomes
Sustained Virologic Response 12 Weeks after Treatment Completion (SVR12)
Time Frame: 12 weeks post-treatment
HCV RNA will be measured 12 weeks post-treatment to evaluate SVR
Secondary Outcomes
- Sustained Virologic Response 4 and 24 Weeks after Treatment Completion(4 and 24 weeks post-treatment)